Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Mol Biol Rep
; 49(1): 827-831, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1536338
ABSTRACT
BACKGROUND:
The global COVID-19 pandemic is currently underway. A massive worldwide vaccination campaign is still underway, representing the most promising weapon available to stop the pandemic. METHODS ANDRESULTS:
However, research continues to investigate the most effective drug treatments to reduce and avoid the most serious complications caused by COVID-19 infection. Recently, new evidence of good therapeutic efficacy against COVID-19 has emerged for the antiviral Remdesivir and the immunomodulatory Baricitinib, also in combination. The first one showed SARS-CoV-2 antireplicative activity, the second one useful to reduce the hyperinflammatory state caused by cytokine storm in the most severe phases of the infection.CONCLUSIONS:
In this short communication we describe the molecular pharmacological mechanisms and the latest evidence for the use of these therapeutic agents in the treatment of COVID-19 infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purines
/
Pyrazoles
/
Sulfonamides
/
Azetidines
/
Adenosine Monophosphate
/
Alanine
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Adult
/
Humans
Language:
English
Journal:
Mol Biol Rep
Year:
2022
Document Type:
Article
Affiliation country:
S11033-021-06888-8
Similar
MEDLINE
...
LILACS
LIS